NCT06741111已完成不适用
A Real-world Assessment in Implementation of the MASH Patient Care Pathway in Chinese Population Using the Meinian Health Check-up Database
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 1,233,970
- 试验地点
- 1
- 主要终点
- The proportion of people with low/intermediate/high risk of advanced fibrosis in EASL at risk population based on EASL 2024 care pathway.
研究概览
简要总结
The primary objective of this study is to estimate the proportion of people with low/intermediate/high risk of advanced fibrosis in at risk Chinese population based on the European Association for the Study of the Liver (EASL) 2024 care pathway
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •For All and Study population:
- •Male or female, age above or equal to 18 years on health-check-up visit day
- •No missing value on sex
- •For EASL at risk population
- •Must be part of study population.
- •People with T2D or [obesity＋above or equal to 1 cardiometabolic risk factor(s)] or elevated liver enzymes
- •For EASL not at-risk population
- •Must be part of study population.
- •For EASL-SAFE
- •Must be part of EASL at risk population
- •For AGA at risk population
- •Must be part of study population.
- •People with 2 or more metabolic risk factors (EASL-MASLD criteria) or T2D or steatosis on any imaging modality or with elevated aminotransferases
- •For CSH MAFLD population
- •Must be part of study population.
- •Liver steatosis on abdominal ultrasound
- •With at least one component of Metabolic syndrome (MetS [CSH])
排除标准
- •Individuals originating from centers with fewer than 100 participants
- •Missing value of liver stiffness measurement (LSM)
- •Had an interquartile range/median ratio above or equal to 30% of the measurement of LSM
- •Missing value on either aspartate aminotransferase (AST) or alanine aminotransferase (ALT) or platelet count (PLT)
- •Missing value on FPG, TG, HDLc or BP (to define the presence of metabolic risk factors)
- •Missing value on abdominal ultrasound
- •For EASL not at-risk population
- •People with T2D or [obesity＋above or equal to 1 cardiometabolic risk factor(s)] or elevated liver enzymes
- •For EASL-SAFE/NFS
- •Missing value on globulin
结局指标
主要结局
The proportion of people with low/intermediate/high risk of advanced fibrosis in EASL at risk population based on EASL 2024 care pathway.
时间窗: January 1st, 2023, to December 31st, 2023
Number and proportion of people in respective risk population
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Retrospective Evaluation of the Percentage of Subjects Who Have Reached Their LDL-C Objectives After Treatment With INEGY (Study P05103)(COMPLETED)Primary HypercholesterolemiaNCT00724477Organon and Co1,663
已完成
早期 1 期
A Study for the Identification of Biomarker Signatures for Diagnosis of Pulmonary Hypertension (PH) in Participants at Low or Intermediate Probability of PH Undergoing Cardiac Magnetic Resonance ImagingHypertension, PulmonaryNCT04480723Actelion86
已完成
不适用
A Registry of Patients With Moderate to Severe Plaque PsoriasisPsoriasisNCT02786186Novartis Pharmaceuticals2,376
已完成
3 期
A Study in Underrepresented Patient Population or Regimen Tolerability: SUPPoRTHuman Immunodeficiency Virus InfectionsNCT00727597Georgetown University101
已完成
不适用
LLLT for Reducing Waste Circumference and WeightWeight LossNCT02877004Mayo Clinic60